Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, United States

Survival: 12.6 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, MA
Hospital: Dana-Farber/Brigham and Women's Cancer Center
Journal: Link
Date: 4/2008

Patients: This phase II study involved fifty patients with newly diagnosed glioblastoma. There were 18 women and 32 men; their median age was 54, ranging from 29-78 years of age.

Treatment: Patients were treated with temozolomide (chemotherapy), thalidomide, and celecoxib (biological therapies).

Toxicity: One patient died from neutropenia and fever that was related to the treatment. Grade 4 toxicities included neutropenia in two patients, thrombocytopenia in 3 patients, thrombosis in 2 patients, and leucopenia in 2 patients. Grade 3 toxicites included agitation, constipation, leucopenia, fatigue, neutropenia, seizure, thrombocytopenia, and thrombosis. The most common grade 3 toxicities were leucopenia and neutropenia, occurring in 8 and 9 patients, respectively.

Results: The median overall survival was 12.6 months from the time they were enrolled in the study.

Support: This research was supported in part by funds from Schering Plough and Celgene corporations. Thalidomide is marketed by Celgene as Thalomid® , and temozolomide is marketed by Schering Plough as Temodar®.

Correspondence: Dr. Patrick Y. Wen

E-mail to a Friend Email Physician More Information